Innovation Technology
Innovative NeuroTechnologies Inc. (INT) is a biotechnology company operating in a virtual mode, dedicated to developing biologically-based and disease-modifying therapeutic solutions for neurodegenerative disorders known as tauopathies. By focusing on the Tau protein, INT aims to create a pipeline of biotherapeutic candidates to prevent or mitigate cognitive decline associated with conditions such as Alzheimer's disease and Frontotemporal dementia.
INT has been recognized for its innovative approaches, recently awarded a Phase I SBIR grant from the National Institutes of Health to conduct efficacy studies on a novel delivery method for anti-Tau therapies. The company is committed to targeting niche genetic disorders and streamlining clinical development to more effectively advance its therapeutic projects.
Generated from the website


